Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

November 30, 1997

Primary Completion Date

February 28, 2007

Conditions
Sarcoma
Interventions
BIOLOGICAL

filgrastim

DRUG

ifosfamide

DRUG

paclitaxel

Trial Locations (17)

10466

MBCCOP-Our Lady of Mercy Cancer Center, The Bronx

19104

Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

46601

CCOP - Northern Indiana CR Consortium, South Bend

55455

University of Minnesota Cancer Center, Minneapolis

61801

CCOP - Carle Cancer Center, Urbana

70121

CCOP - Ochsner, New Orleans

76508

CCOP - Scott and White Hospital, Temple

89106

CCOP - Southern Nevada Cancer Research Foundation, Las Vegas

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

94305-5216

Stanford Cancer Center at Stanford University Medical Center, Stanford

46202-5289

Indiana University Cancer Center, Indianapolis

02111

Tufts - New England Medical Center, Boston

03756-0002

Norris Cotton Cancer Center at Dartmouth Medical School, Lebanon

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

19111-2497

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Eastern Cooperative Oncology Group

NETWORK

lead

Gynecologic Oncology Group

NETWORK

NCT00003128 - Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus | Biotech Hunter | Biotech Hunter